1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Notice of Special Interest (NOSI): Research on the Mechanisms of Pain in Sickle Cell Disease is sponsored by National Heart, Lung, and Blood Institute (NHLBI). This NOSI specifically encourages research into the mechanisms underlying pain in Sickle Cell Disease (SCD), including the role of inflammation and innate immune signaling.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-HL-21-037: Notice of NHLBI Participation in NOT-AT-21-002 "Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease (R01) Notice of NHLBI Participation in NOT-AT-21-002 "Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease (R01) NOT-AT-21-002 - Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required) PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) National Heart, Lung, and Blood Institute ( NHLBI ) The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in NOT-AT-21-002 "Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease".
For this NOSI, NHLBI is interested in basic, translational, and clinical research to examine interoceptive processes and mechanisms mediating heart, lung, blood, and sleep (HLBS) normal biological function, resilience, and disease pathophysiology.
Topics of interest include, but are not limited to: Changes in interoceptive processes that might lead to alterations in HLBS function under normal conditions at the cell, tissue, and systemic levels.
Disruptions in interoceptive processes that might lead to or exacerbate the development, progression, and manifestations of arrhythmias, heart failure, hypo- and hypertension, postural orthostatic tachycardia syndrome, dyspnea, chronic cough, sleep and circadian rhythms disorders, and sickle cell disease pain. Impact on interoceptive systems by HLBS disease-related structural and functional remodeling in cardiopulmonary neural circuits.
Computational integrative approaches elucidating autonomic nervous system pathophysiology and modeling neuromodulation-based personalized therapies for HLBS diseases. Effects of changes in sympathetic and parasympathetic tone in heart failure on other organs or alterations neuroendocrine signaling in other tissues. Elucidation of sleep-related interoceptive processes (e.g., the perception of sleep quality, sleepiness, and fatigue).
Investigation of how disruptions in interoceptive processes might lead to, accelerate, or exacerbate vascular contributions to cognitive impairment and dementia, and vice versa, how cognitive deficiencies associated with vascular diseases might impact interoceptive systems.
Research on microbiota dysbiosis in the lungs and gut and how its effects on hypersensitivity and altered pain perception could be explored in therapeutic interventions. Identify acute vs. chronic effects of abnormal respiratory interoception in lung disorders. Development of clinically relevant protocols for manipulating respiratory interoception for disease intervention.
Establishment of pre-clinical models for assessment of pulmonary neuroimmunoregulation, microbiomes, and development of interventional targets. Identification of cardiovascular and respiratory interoceptive markers with diagnostic and prognostic value. Research on blood immune cell interactions with heart and lungs.
Interaction of peripheral and central nervous systems with bone marrow cells to regulate hematopoietic system function during development, homeostasis, psychosocial stress, and hematopoietic stem cell transplantation. Interoceptive mechanisms regulating acute vs. chronic sickle cell disease pain.
Development and testing of interventions to increase interoceptive awareness of hunger/satiety in patients with obesity and symptom perception in patients with cardiovascular conditions. Note: For this NOSI, NHLBI will only accept applications that target PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) and PA-20-183 NIH Research Project Grant (Parent R01 Clinical Trial Required) .
For PA-20-183 NIH Research Project Grant (Parent R01 Clinical Trial Required), NHLBI only accepts mechanistic studies that meet NIH's definition of a clinical trial . Please direct all inquiries to: Scientific/Research Contact National Heart, Lung, and Blood Institute Division of Cardiovascular Sciences Financial/Grants Management Contact Weekly TOC for this Announcement NIH... Turning Discovery Into Health ®
According to the current listing, eligibility includes: Higher education institutions (HBCUs like MSM are prioritized for diversity-focused mechanisms); Non-profits with 501(c)(3) status. Confirm the full requirements in the official notice before applying.
The current listing shows varies by grant mechanism (e.g., R01 up to $500,000/year). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Notice of Special Interest (NOSI): Research on the Mechanisms of Pain in Sickle Cell Disease is funded by National Heart, Lung, and Blood Institute (NHLBI). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start with the full solicitation document linked on this page — it contains the submission instructions and required forms.
Five NHLBI Catalyze Product Definition RFAs — HL-26-016 through HL-26-020 — carry an October 21, 2026 receipt date, budget caps of $300,000 to $400,000 per year, and roughly 8 new awards annually. The science is not the gate. An Accelerator Partner and a 0.25:1 non-federal cost match are, and both take longer to line up than the nine weeks you have left.
Read articleThe $46M FSHARP program is creating shelf-stable synthetic blood from freeze-dried components. A new SWiFT SBIR topic opened May 6 for autonomous field transfusion devices. What grant seekers in biomedical engineering need to know.
Read articleDARPA MTO opened six FY26 SBIR topics on May 27 with a June 24 deadline — nanopore proteomics, compact RF filters, 800°C ICs, passive thermal spreaders, radiation-hardened codesign, and low-resource computing. The topics read like a wishlist for the next decade of contested-environment microelectronics. Here is what each one is actually asking for, and how small businesses should triage the four-week window.
Read article